|
Albuquerque, NM (Jan. 11,
2010) – Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD)
will present information on its proprietary CyPath® diagnostic
assay for the detection of early-stage lung cancer at the
OneMedPlace Finance Forum on Tuesday, Jan. 12, 2010, in San
Francisco.
The OneMedPlace Finance
Forum connects emerging companies in the healthcare and life
science industries with investors and strategic partners that can
help bring new technologies to the marketplace.
“We are delighted to have
the opportunity to showcase our technology before a large number
of qualified investors who operate specifically in the healthcare
sector. This audience is going to immediately understand the
market potential for a non-invasive, inexpensive and accurate
screening tool for lung cancer,” said Biomoda President and
Chief Executive Officer John Cousins.
Currently in clinical
trials, the Biomoda diagnostic is a porphyrin application
originally developed at the Los Alamos National Laboratory that
preferentially binds to cancerous or aberrant cells extracted from
deep lung sputum samples. Cancerous cells treated with Biomoda’s
patented CyPath® labeling solution fluoresce red under
ultraviolet light. Until the diagnostic receives FDA
approval, it may be used for investigational purposes only.
“Lung cancer is the
deadliest cancer, primarily because it is too often diagnosed in
the late stages when it has metastasized beyond the lungs,”
Cousins said. “A screening technology that can identify
cancer at the cellular level has the potential to save hundreds of
thousands of lives. That’s the message we are taking to
the OneMedPlace Forum.”
Biomoda is one of 114
companies presenting over the two-day conference Jan. 12-13 at the
Sir Francis Drake Hotel in San Francisco. In addition to
company presentations, panels made up of leading investors,
analysts, business development executives, CEOs and clinical
opinion leaders will address advances in six therapeutic areas:
oncology, obesity and metabolic disorders, diagnostics and
personalized medicine, neurology, cardiology, and ophthalmology.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are based on
estimates, projections, beliefs and assumptions of Biomoda
management at the time of such statements and are not guarantees
of future performance. Forward-looking statements involve risks
and uncertainties in predicting future results and conditions.
Actual results could differ materially from those projected in
these forward-looking statements due to a variety of factors,
including, without limitation, the acceptance by customers of our
products, our ability to develop new products cost-effectively,
our ability to raise capital in the future, the development by
competitors of products using improved or alternative technology,
the retention of key employees and general economic conditions.
Forward-looking statements are made as of the date of this press
release and are subject to change without notice.
CONTACT:
Biomoda, Inc.
John
Cousins
505.821.0875
investor@biomoda.com
|
